Section Arrow
CRVS.NASDAQ
- Corvus Pharmaceuticals
Quotes are at least 15-min delayed:2026/01/09 11:19 EST
Regular Hours
Last
 6.96
+0.04 (+0.58%)
Day High 
Prev. Close
6.92 
1-M High
9.205 
Volume 
261.10K 
Bid
6.96
Ask
6.97
Day Low
6.85 
Open
6.9 
1-M Low
6.43 
Market Cap 
516.80M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 7.26 
20-SMA 7.62 
50-SMA 8.05 
52-W High 9.6 
52-W Low 2.54 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.54/-0.60
Enterprise Value
517.74M
Balance Sheet
Book Value Per Share
0.96
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
SLSSELLAS Life Sciences Group3.485-0.375-9.72%-- 
ASBPAspire Biopharma Holdings Inc.0.0992-0.0041-3.97%-- 
IBIOiBio2.65+0.3+12.77%0.65PE
ARDXArdelyx7.7489+0.7489+10.70%-- 
MREOMereo BioPharma Group plc0.4036+0.0192+4.99%-- 
Industry overview quotes are at least 15 minutes delayed
Business Description
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.